



# The Study of Mutation in *LasR* and *PqsR* Genes in Extremely Drug Resistant and Multidrug Resistant Strains of *Pseudomonas aeruginosa* from Burn Wound Infection

Seyed Abolfazl Hosseininasab Nodoushan<sup>1</sup>, Sharareh Moghim<sup>1</sup>, Nasrin Mirzaei<sup>2</sup> and Hajieh Ghasemian Safaei<sup>1\*</sup>

<sup>1</sup>Department of Microbiology, Isfahan University of Medical Sciences, Isfahan, Iran

<sup>2</sup>Department of Microbiology, Tonekabon Branch, Islamic Azad University, Tonekabon, Iran

\*Corresponding author: Department of Microbiology, Isfahan University of Medical Sciences, Isfahan, Iran. Tel: +98-3137922469, Email: minaghsafaei@gmail.com

Received 2019 May 22; Revised 2019 October 25; Accepted 2019 October 26.

## Abstract

**Background:** *Pseudomonas aeruginosa* is among the top 10 resistant bacteria worldwide. Its extraordinary resistance is principally due to the function of quorum sensing genes, such as *lasR* and *pqsR*, which are mainly involved in antibiotic resistance.

**Objectives:** This study aimed to examine possible mutations in *lasR* and *pqsR* in resistant clinical isolates of *P. aeruginosa*.

**Methods:** We obtained 120 suspected isolates of *P. aeruginosa* from burn patients. The isolates were identified by biochemical tests and *toxA* gene analysis. The PCR products of *LasR* and *PqsR* genes were analyzed in seven resistant isolates. Then, the sequences were compared with a reference strain.

**Results:** We verified Ninety-six isolates as absolute *P. aeruginosa*. According to antibiograms, 95.8% of the isolates were considered as multidrug-resistant, of which 87.5% were extensively drug-resistant. Based on DNA and protein sequences, only one missense mutation was observed, including R180Q in *lasR* and A314V in *pqsR*. While R180Q decreased the stability of *LasR* and had a deleterious impact on protein function, A314V had a neutral impact on the protein and increased *PqsR* protein stability. Also, two nonsense mutations in position E259 were observed in the *PqsR* protein.

**Conclusions:** The *lasR* and *pqsR* genes possibly can play a key role in antibiotic resistance, but they are not the only factors. Hence, studying mutations helps design a promising antibiotic to overcome antibiotic resistance as much as possible.

**Keywords:** *Pseudomonas aeruginosa*, Drug Resistance, Genes, Regulator

## 1. Background

*Pseudomonas aeruginosa* is a Gram-negative bacillus. It is a ubiquitous bacterium that can be found in a wide range of environments. The National Nosocomial Infection Surveillance System has declared *P. aeruginosa* as a leading cause of nosocomial infections, including septicemia, cystic fibrosis, burn wound, respiratory and urinary infections (1-3). *Pseudomonas aeruginosa* infections have become a real concern since many of the available antibiotics appear to be poorly effective against this bacterium. Besides, the excessive use of antibiotics during treatment accelerates the ineffectiveness of empirical antibiotic therapy against *P. aeruginosa* (4). Hence, the Center for Disease Control and Prevention has placed *P. aeruginosa* among the top 10 resistant bacteria worldwide.

The extraordinary resistance and pathogenicity of *P. aeruginosa* are principally due to the function of quorum

sensing (5). Quorum Sensing (QS), a cell-cell communication system, plays a critical role in survival and colonization and is responsible for controlling more than 10% of *P. aeruginosa* genes. These genes are mainly involved in antibiotic resistance, motility, production of virulence factors, and biofilm formation (6). Among the QS genes, the dominant regulator is called the *las* system, which utilizes Acylated Homoserine Lactones (AHLs) for signaling. The synthase of *las* QS is termed *LasI*, which stimulates receptor *LasR* (1). *LasR* homodimerizes after binding their signal molecules and prompting their transcription. On the other hand, *PqsR* (known as *MvfR*) is a transcriptional regulator that links to the promoter area of the *pqsABCDE* operon and instantly regulates its expression to produce an auto-regulatory loop (7). Apart from its intrinsic resistance, *P. aeruginosa* possesses an outstanding ability to develop resistance through the selection of mutations in a

complex network of genes implicated in resistance and gene regulation (8). Noticeably, mutations can affect protein expression, subcellular localization, protein folding and stability, and protein function (9). An increasing pool of evidence suggests that the amino acid sequence of a protein determines its final structure, which, in turn, determines its function. Protein destabilization or some abnormal biological functions would be the results of these mutations. While the majority of non-synonymous Single-nucleotide Polymorphisms (nsSNPs) seem to be functionally neutral, the others show functional consequences and may cause or influence diseases. When engineering proteins, it is vital to know the extent of mutation impact on the stability of new proteins in contrast to the wild-type (10). The increasing trend in antibiotic resistance has caught attention to the improvement of new treatment strategies, such as reducing bacterial virulence through QS (11).

Since the QS system plays a crucial role in regulating *P. aeruginosa* virulence, it is regarded as a promising drug target. Seemingly, the suppression of the QS system converts pathogenic *P. aeruginosa* into nonpathogenic without using standard antibiotics; it is a new strategy of antibacterial therapy (12). That is why identifying and reporting new variants that are likely to be pathogenic are significant to study.

## 2. Objectives

This study aimed to examine the possible mutations in *lasR* and *pqsR* genes in extremely drug resistant (XDR) and multidrug resistant (MDR) strains of *P. aeruginosa* from burn wound infection.

## 3. Methods

### 3.1. Identification of Clinical Isolates

In this study, 120 samples belonging to burn patients from Imam Musa Kazem burn injury hospital were sent to the microbiology laboratory of the Isfahan University Medical Sciences, Isfahan, for identification and other processes between January and June 2015. The clinical isolates were plated on blood agar (Merck, Germany) and Cetrimide agar (Merck, Germany). Then, the plates were incubated at 42°C aerobically for 24 hours. The bacteria shape and colony morphology were assessed. We also conducted standard microbiological tests, including catalase, oxidase, triple sugar iron agar, indole production, and oxidative-fermentative tests (Merck, Germany) (Figure 1).




Figure 1. The subculture of isolates on blood agar

### 3.2. Antibiotic Susceptibility Testing

We chose 10 types of antibiotics (Mast, England; Padtan Teb, Iran) to cover a wide range of antibiotic activity for assessing the bacterium behavior. The antibiotics are listed in Table 1. Antibiotic resistance patterns of *P. aeruginosa* isolates were determined by the Kirby-Bauer disc diffusion method according to the Clinical Laboratory Standard Institute (CLSI) guidelines, version 2015. As a reference strain, *P. aeruginosa* ATCC 27853 was used in the present study. First, a microbial suspension (equivalent to 0.5 MacFarland) was prepared directly from standard strain ATCC 27853 and cultured on Mueller Hinton agar (Merck, Germany) for the quality control of antibiotics (13). Finally, discs were placed directly onto the plates and incubated overnight at 37°C. Then, the same procedure was repeated for clinical isolates. The diameter of the inhibition zone was measured and compared to that of the standard strain.

### 3.3. DNA Extraction and Primer Design

The DNA of clinical isolates and reference strain ATCC 27853 was extracted by the boiling method. The concentration and purity of DNA samples were checked by a Nanodrop spectrophotometer (Thermo Fisher Scientific, US). All isolates were tested for the presence of *toxA* as a gene that can inhibit eukaryotic protein biosynthesis at the level of polypeptide chain elongation factor 2. The expected PCR product size for *toxA* was 396 bp (14). The *lasR* and *pqsR* genes were 717 bp and 996 bp in length, respectively. Hence, we designed two sets of primers for each gene to cover the entire gene. First, the whole sequences of *P. aeruginosa lasR* and *pqsR* genes were extracted from the National Center for Biotechnology Information (NCBI) database. The

**Table 1.** Antibiotics Used in This Study

Antibiotic	Class <sup>a</sup>	Resistance Rate (%)
Amikacin	Aminoglycoside	94.8
Gentamicin		82.3
Aztreonam	Beta-lactam	87.5
Ceftazidime		60.4
Piperacillin-Tazobactam	Beta-lactam/ Penicillin	80.2
Meropenem	Carbapenem	88.5
Cefepime	Cephalosporin	80.2
Ciprofloxacin	Fluoroquinolone	89.6
Norfloxacin		90.6
Colistin	Polymyxin	8.3

<sup>a</sup>Based on information in DrugBank (www.drugbank.ca)


conserved parts of the genes were selected by MEGA 6 and imported to Gene runner software for designing a set of primers. The specificity of primers was checked using the primer Blast tool in NCBI (10). Then, the primers with the best specificity were chosen and sent to Metabion Company, Germany, for synthesizing. The designed primers are listed in Table 2. The cycling program included one cycle at 94°C for one minute, 35 cycles of 62°C for one minute, 72°C for one minute, and a final elongation step at 72°C for four minutes. Reference strain *P. aeruginosa* ATCC 27853 was used as positive control (Figure 2).

#### 3.4. Analysis of DNA and Protein Sequences

The PCR products of seven isolates were purified and sequenced by Bioneer Company, Korea. Then, the nucleotide blast program (NCBI) and Clustal Omega program were used to analyze the DNA and protein sequences. The impact of mutations on protein stability and protein function was evaluated by I-Mutant (15), iStable (16), MuPro (17), and PROVEAN (18) webserver. Reference strain PAO1 was selected to compare with.

## 4. Results

Ninety-six isolates of *P. aeruginosa* were grown from 120 burn wound samples. After biochemical tests and Gram staining, the final identification was done based on the *toxA* gene and all the 96 isolates were identified as absolute *P. aeruginosa*. Some of the clinical isolates showed resistance to several antibiotics, named MDR, XDR, and Pandrug Resistant (PDR), owing to the extreme of their resistance. According to the MDR and XDR definitions, XDR isolates are basically part of MDR isolates. Hence, 95.8% of the



**Figure 2.** *lasR1, lasR2, pqsR1, pqsR2*, negative control, and positive control, in sequence

isolates were MDR, of which 87.5% were XDR. Since no PDR isolates were seen in this study, only showed 4.2% of the clinical isolates to be susceptible to treatment (Figure 3). Among the antibiotics used in this study, the most effective antibiotic to treat *P. aeruginosa* infection was colistin from the polymyxin family, whereas the bacterium showed the most resistant rate to amikacin as an aminoglycoside (19). The results are presented in Table 1.

Among the clinical isolates showing resistance to antibiotics, those that had the highest minimum inhibitory concentration (MIC) and were the most resistant isolates, including three MDR and four XDR strains, were selected as the representatives of all isolates and sent for two-way sequencing. All the seven isolates were sequenced for *lasR* and *pqsR* genes. The mutations are listed in Table 3. Among these resistant isolates, five and two isolates were devoid of any mutation in the *lasR* and *pqsR* genes, respectively. These isolates were completely similar to reference strain PAO1. Amongst the isolates assessed for mutations in the *lasR* gene, isolate S-5 had two silent mutations in position L36 and N209 and S-2 had one missense mutation in position 180 which led to substitution R180Q. Apart from this missense mutation, three silent mutations in L36, A121, and

**Table 2.** Primers Used in This Study

Target Gene	Encoded Protein	Primer Sequence	Amplicon (bp)	Ref.
<i>toxA</i>	Exotoxin A	F:5-GACAACGCCCTCAGCATCACCAGC-3	396	(14)
		R:5-CGCTGGCCCATTCGCTCCAGCGCT-3		
<i>lasR1</i>	Transcriptional regulator	F:5-ATCTTCAGGGGTCGTCGGG-3	730	This study
		R:5-ATCTCCCAACTGGCTTGCC-3		
<i>lasR2</i>		F:5-GAAGTGTTCAGTGGTGCG-3	304	This study
		R:5-GGATAAGCCAATCCTGCGG-3		
<i>pqsR1</i>		F:5-GTCAACCCGCTGTCGACG-3	806	This study
		R:5-ACGATCAAGCAGGACAACGC-3		
<i>pqsR2</i>		F:5-GCACGCACTGGTTGAAGC-3	733	This study
		R:5-AAACGACGACTCCCCGTGC-3		



**Figure 3.** Kirby-Bauer disc diffusion method on Mueller Hinton agar

N214 were observed, as well. On the other hand, the assessment of the *pqsR* gene showed that isolate S-1 had one silent mutation in R126 and one nonsense mutation in E259. A similar pattern was repeated for S-6 and the mutations were the same as mutations in S-1. Two silent mutations in R126 and E259 were observed for S-3. Also, this isolate had one missense mutation which led to substitution A314V. There were only two silent mutations in L98 and P177 for S-4 while S-5 had three silent mutations in E152, V215, and E219. Generally speaking, the rate of mutations was more in the *pqsR* gene than in the *lasR* gene.

Since there are many new methods and algorithms to predict amino acid substitutions and their impacts, it would be better to combine these prediction methods and reach a consensus. Hence, we used three predicting programs, including Mupro, iStable, and I-Mutant, to find out the impact of missense mutations on protein stability ob-

**Table 3.** Types of Mutations Seen in the Present Study

Strain	Resistant Status	<i>LasR</i> Mutation	<i>PqsR</i> Mutation
S-1	XDR	No mutation	Silent (R126), Nonsense (E259-)
S-4		No mutation	Silent (L98, P177)
S-5		Silent (L36, N209)	Silent (E152, V215, E219)
S-7		No mutation	No mutation
S-2	MDR	Silent (L36, A121, N214), Missense(R180Q)	No mutation
S-3		No mutation	Silent (R126, E259), Missense (A314V)
S-6		No mutation	Silent (R126), Nonsense (E259-)

<sup>a</sup>The results of biochemical tests are as follows: catalase (+), oxidase (+), indole production (-), OF test (oxidative) and TSI (alkaline/alkaline, no gas and H<sub>2</sub>S production)

served in the present study. Also, the impact of missense mutations on the biological function of proteins was assessed by PROVEAN. According to Table 4, the only missense mutation in *LasR* (R180Q) decreased the stability of the *LasR* protein and had a deleterious impact on protein function, whereas substitution A314V in *PqsR* led to increased protein stability along with a neutral impact on protein function. The majority of programs could not assess the impact of nonsense mutations, but it is obvious that nonsense mutations could produce truncated and nonfunctional proteins as expected. Even though both missense mutations happened in MDR strains, nonsense mutations were seen in both XDR and MDR isolates.



**Table 4.** Analysis of Protein Stability and Protein Function

Protein	Site	Protein Stability						Protein Function		
		Mupro		iStable		I-Mutant		Consensus	PROVEAN	
		$\Delta\Delta G$	Stability	Score	Stability	$\Delta\Delta G$	Stability		Score	Prediction
LasR	R180Q	-1.028	↓	0.738	↓	-0.86	↓	Decrease	-3.864	Deleterious
PqsR	A314V	0.241	↑	0.565	↑	-0.11	↓	Increase	-0.004	Neutral

Abbreviation:  $\Delta\Delta G$ , the difference in folding free energy change between wild type and mutant proteins

## 5. Discussion

Microbial drug resistance has become a serious clinical and public health problem. The mechanisms of drug resistance have become a focal point of research in recent years (20). The magnitude of this problem has heightened due to the rapid genetic changes in genes involved in antibiotic resistance even to the most recently developed drugs (21). Mutations in the genes of infectious organisms play a primary role in resistance and this leads to changes in drug interaction with its target protein (22). This scenario has signified the importance of studying mutations in responsible genes.

There is a large body of evidence that mutations in QS systems can interfere with the ability of *P. aeruginosa* to cause general and local damage in burn wound infection (23). Thereby, mutations in QS genes of *P. aeruginosa* caused it to lose its pathogenic potential compared to wild type strains (24). This infection can lead to graft loss, prolonged hospital stay, systemic sepsis, and even increased mortality in burn units (25); hence, the colonization rates have increased to 50% among hospitalized patients. Also, prolonged antibiotic therapy makes this scenario worse by the disruption of normal microbial flora (26).

The *lasR* gene encodes a protein critical for the initiation of QS response involved in virulence factor production and biofilm formation, signifying that other factors controlled by *lasR* are critical determinants of *P. aeruginosa* pathogenesis in burn wound infection (27). However, *P. aeruginosa* strains with mutations in *lasR* have been predominately isolated from infections and emerged during in vitro evolution (28). In contrast, we found out five silent and one missense mutations in the *LasR* protein sequence, but five of the clinical isolates were devoid of any mutation, signifying that other mechanisms are probably involved. It seems that the loss of QS regulation as a result of the accumulation of mutations in the key QS regulator, *LasR*, is especially common among patients with cystic fibrosis (29). Basically, *P. aeruginosa* acute virulence in diverse model hosts can be reduced as a result of the inactivation of *lasR*, whereas the loss of *LasR* function may represent a marker of early-stage chronic infection of the cystic

fibrosis airway with clinical implications for antibiotic resistance and disease progression (30). In the present study, silent mutations prevailed over other types of mutations. On the other hand, it is strongly supposed that the inactivation of *lasR* is probably associated with conferring resistance to antibiotics (31), while we observed only one missense mutation with a detrimental impact on protein sequence. The sequences assessed here were completely resistant to antibiotics so that three of them were MDR and the others were XDR. López-Causapé et al. reported the main antibiotic resistance mutations among which, P117G was dominant (32); it is in contrast to our study, but it should be mentioned that silent mutations in position L36 happened in two clinical isolates.

Bottomley et al. reported atomic interactions between protein *LasR* and its autoinducer. The amino acid residues involved in these interactions included Tyrosine-56, Arginine-61, Aspartate-73, Threonine-115, and Serine-129. These residues can bind concurrently to cause protein folding, leading to the dimerization of *LasR*, thus allowing for DNA binding to the promoter and consequent transcriptional activation of QS-controlled genes. Furthermore, Bjarnsholt et al. reported that mutations in Tyrosine-56 and Threonine-75 in the *lasR* protein would impair autoinducer binding since they strongly interact with the autoinducer (33). In contrast, we did not find any mutation in this region, but we found that missense mutations in region Arginine 180 (R180Q) had a damaging effect on protein function; this also reduced the stability of the protein when compared to strain PAO1. Compared to this missense mutation, silent mutations were observed in positions L36, A121, N209, and N214. It should be noted that several transcriptional regulators, which belong to QS, were expressed at a higher level in PAO1 than in ATCC 27853; moreover, the complete genome of strain ATCC 27853, which usually is used to survey antibiotic susceptibility, is still lacking (34). That is why many studies make comparisons with reference strain PAO1.

In a study, the importance of Gln194 or Tyr258 for *PqsR* function was assessed by constructing full-length *PqsR* mutants with mutations at either mentioned positions. The

results of this investigation indicated that although Q194E retained at least 88% functionality, this mutant was virtually inactive and almost failed to respond to the *Pseudomonas* quinolone signal in the *pqsA* mutant. On the other hand, a hydrophobic amino acid at position 258 is required for *PqsR* functionality since Y258A mutation renders *PqsR* inactive (35). No mutations at positions 194 and 258 were seen in our study, but the only missense mutation in the present study (A314V) increased protein stability along with having a neutral impact on protein function. As indicated by previous studies, the mutation of *pqsR* ends up in the termination of *phnAB* and *pqsABCDE* expression, implying *PqsR* is crucial for PQS signal transduction.

Null mutants of the *pqs* system decreased biofilm development and reduced the generation of virulence factors, including some enzymes. The *pqs* system is also required for complete *P. aeruginosa* virulence toward plants, nematodes, and mice (7). Apart from the missense mutation, there was a nonsense mutation at position 259 (E259-), which was repeated in two isolates. Since the PROVEAN web server cannot assess the impact of nonsense mutations, there is a consensus about nonsense mutations that have a more dramatic change than missense mutations and result in a premature stop codon, produce truncated and typically nonfunctional proteins (36). Furthermore, these nonsense mutations are more likely to have pathogenic consequences due to disrupting protein structure; they have also more disadvantageous effects than nonsynonymous mutations (37, 38).

### 5.1. Conclusions

In summary, *lasR* and *pqsR* possibly can play a key role in antibiotic resistance, but they are not the only factors and environmental elements possibly involved in this matter. Since geographical differences are important in resistance-related mutations and drug efficacy, further investigations with a large number of strains are required. Overall, the accumulation of mutations in a gene is a common reason for antibiotic resistance. Hence, studying mutations is necessary to understand the repertoire of molecular mutations and recognize the conserved and variable residues. Moreover, it helps predict the emergence and spread of resistance mutations in genes and design a promising antibiotic with the ability to overcome antibiotic resistance as much as possible.

### Footnotes

**Authors' Contribution:** The authors contributed equally to this work.

**Conflict of Interests:** No conflict of interest is declared by the authors.

**Ethical Approval:** This study was conducted at the Department of Microbiology, Isfahan University of Medical Sciences. Furthermore, the study was approved by the Ethics Board of Isfahan University of Medical Sciences (Grant No., 394656).

**Funding/Support:** This study was supported by the Isfahan University of Medical Sciences, Isfahan, Iran (Grant No., 394656).

**Informed Consent:** All participants signed written informed consent forms before the study.

### References

- Wagner S, Sommer R, Hinsberger S, Lu C, Hartmann RW, Empting M, et al. Novel strategies for the treatment of *Pseudomonas aeruginosa* infections. *J Med Chem.* 2016;**59**(13):5929–69. doi: [10.1021/acs.jmedchem.5b01698](https://doi.org/10.1021/acs.jmedchem.5b01698). [PubMed: 26804741].
- Alnour TM, Ahmed-Abakur EH. Multidrug resistant *Pseudomonas* (*P*) *aeruginosa*: Medical impact, pathogenicity, resistance mechanisms and epidemiology. *JSM Microbiol.* 2017;**5**(3):1046.
- Mulcahy LR, Isabella VM, Lewis K. *Pseudomonas aeruginosa* biofilms in disease. *Microb Ecol.* 2014;**68**(1):1–12. doi: [10.1007/s00248-013-0297-x](https://doi.org/10.1007/s00248-013-0297-x). [PubMed: 24096885]. [PubMed Central: PMC3977026].
- Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. Antibiotic resistance in *Pseudomonas aeruginosa*: Mechanisms and alternative therapeutic strategies. *Biotechnol Adv.* 2019;**37**(1):177–92. doi: [10.1016/j.biotechadv.2018.11.013](https://doi.org/10.1016/j.biotechadv.2018.11.013). [PubMed: 30500353].
- Rezaie P, Pourhajbagher M, Chiniforush N, Hosseini N, Bahador A. The effect of quorum-sensing and efflux pumps interactions in *Pseudomonas aeruginosa* against photooxidative stress. *J Lasers Med Sci.* 2018;**9**(3):161–7. doi: [10.15171/jlms.2018.30](https://doi.org/10.15171/jlms.2018.30). [PubMed: 30809326]. [PubMed Central: PMC6378363].
- Moradali MF, Ghods S, Rehm BH. *Pseudomonas aeruginosa* lifestyle: A paradigm for adaptation, survival, and persistence. *Front Cell Infect Microbiol.* 2017;**7**:39. doi: [10.3389/fcimb.2017.00039](https://doi.org/10.3389/fcimb.2017.00039). [PubMed: 28261568]. [PubMed Central: PMC5310132].
- Lin J, Cheng J, Wang Y, Shen X. The *Pseudomonas* Quinolone Signal (PQS): Not just for quorum sensing anymore. *Front Cell Infect Microbiol.* 2018;**8**:230. doi: [10.3389/fcimb.2018.00230](https://doi.org/10.3389/fcimb.2018.00230). [PubMed: 30023354]. [PubMed Central: PMC6039570].
- Mensa J, Barberan J, Soriano A, Llinares P, Marco F, Canton R, et al. Antibiotic selection in the treatment of acute invasive infections by *Pseudomonas aeruginosa*: Guidelines by the Spanish Society of Chemotherapy. *Rev Esp Quimioter.* 2018;**31**(1):78–100. [PubMed: 29480677]. [PubMed Central: PMC6159363].
- Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: Application to cancer genomics. *Nucleic Acids Res.* 2011;**39**(17). e118. doi: [10.1093/nar/gkr407](https://doi.org/10.1093/nar/gkr407). [PubMed: 21727090]. [PubMed Central: PMC3177186].
- Mirzaei N, Poursina F, Moghim S, Ghaempanah AM, Safaei HG. The bioinformatics report of mutation outcome on NADPH flavin oxidoreductase protein sequence in clinical isolates of *H. pylori*. *Curr Microbiol.* 2016;**72**(5):596–605. doi: [10.1007/s00284-016-0992-1](https://doi.org/10.1007/s00284-016-0992-1). [PubMed: 26821239].
- Yang L, Rybtke MT, Jakobsen TH, Hentzer M, Bjarnsholt T, Givskov M, et al. Computer-aided identification of recognized drugs as *Pseudomonas aeruginosa* quorum-sensing inhibitors. *Antimicrob Agents Chemother.* 2009;**53**(6):2432–43. doi: [10.1128/AAC.01283-08](https://doi.org/10.1128/AAC.01283-08). [PubMed: 19364871]. [PubMed Central: PMC2687250].
- Khmel IA, Metlitskaya AZ. Quorum sensing regulation of gene expression: A promising target for drugs against bacterial pathogenicity. *Mol Biol.* 2006;**40**(2):169–82. doi: [10.1134/s0026893306020014](https://doi.org/10.1134/s0026893306020014).

13. Hombach M, Jetter M, Blochliher N, Kolesnik-Goldmann N, Keller PM, Bottger EC. Rapid disc diffusion antibiotic susceptibility testing for *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and *Enterococcus* spp. *J Antimicrob Chemother.* 2018;**73**(2):385–91. doi: [10.1093/jac/dkx404](https://doi.org/10.1093/jac/dkx404). [PubMed: [29186434](https://pubmed.ncbi.nlm.nih.gov/29186434/)]. [PubMed Central: [PMC5890698](https://pubmed.ncbi.nlm.nih.gov/PMC5890698/)].
14. Khan AA, Cerniglia CE. Detection of *Pseudomonas aeruginosa* from clinical and environmental samples by amplification of the exotoxin A gene using PCR. *Appl Environ Microbiol.* 1994;**60**(10):3739–45. [PubMed: [7986047](https://pubmed.ncbi.nlm.nih.gov/7986047/)]. [PubMed Central: [PMC201881](https://pubmed.ncbi.nlm.nih.gov/PMC201881/)].
15. Capriotti E, Fariselli P, Casadio R. I-Mutant2.0: Predicting stability changes upon mutation from the protein sequence or structure. *Nucleic Acids Res.* 2005;**33**(Web Server issue):W306–10. doi: [10.1093/nar/gki375](https://doi.org/10.1093/nar/gki375). [PubMed: [15980478](https://pubmed.ncbi.nlm.nih.gov/15980478/)]. [PubMed Central: [PMC1160136](https://pubmed.ncbi.nlm.nih.gov/PMC1160136/)].
16. Chen CW, Lin J, Chu YW. iStable: Off-the-shelf predictor integration for predicting protein stability changes. *BMC Bioinformatics.* 2013;**14** Suppl 2. S5. doi: [10.1186/1471-2105-14-S2-S5](https://doi.org/10.1186/1471-2105-14-S2-S5). [PubMed: [23369171](https://pubmed.ncbi.nlm.nih.gov/23369171/)]. [PubMed Central: [PMC3549852](https://pubmed.ncbi.nlm.nih.gov/PMC3549852/)].
17. Cheng J, Randall A, Baldi P. Prediction of protein stability changes for single-site mutations using support vector machines. *Proteins.* 2006;**62**(4):1125–32. doi: [10.1002/prot.20810](https://doi.org/10.1002/prot.20810). [PubMed: [16372356](https://pubmed.ncbi.nlm.nih.gov/16372356/)].
18. Choi Y, Chan AP. PROVEAN web server: A tool to predict the functional effect of amino acid substitutions and indels. *Bioinformatics.* 2015;**31**(16):2745–7. doi: [10.1093/bioinformatics/btv195](https://doi.org/10.1093/bioinformatics/btv195). [PubMed: [25851949](https://pubmed.ncbi.nlm.nih.gov/25851949/)]. [PubMed Central: [PMC4528627](https://pubmed.ncbi.nlm.nih.gov/PMC4528627/)].
19. Hosseininasab Nodoushan SA, Yadegari S, Moghim S, Isfahani BN, Fazeli H, Poursina F, et al. Distribution of the strains of multidrug-resistant, extensively drug-resistant, and pandrug-resistant *Pseudomonas aeruginosa* isolates from burn patients. *Adv Biomed Res.* 2017;**6**:74. doi: [10.4103/abr.abr\\_239\\_16](https://doi.org/10.4103/abr.abr_239_16). [PubMed: [28706882](https://pubmed.ncbi.nlm.nih.gov/28706882/)]. [PubMed Central: [PMC5501067](https://pubmed.ncbi.nlm.nih.gov/PMC5501067/)].
20. Chen YF, Liu SY, Liang ZB, Lv MF, Zhou JN, Zhang LH. Quorum sensing and microbial drug resistance. *Yi Chuan.* 2016;**38**(10):881–93. doi: [10.16288/j.ycz.16-141](https://doi.org/10.16288/j.ycz.16-141). [PubMed: [27806929](https://pubmed.ncbi.nlm.nih.gov/27806929/)].
21. Kalia VC, Purohit HJ. Quenching the quorum sensing system: Potential antibacterial drug targets. *Crit Rev Microbiol.* 2011;**37**(2):121–40. doi: [10.3109/1040841X.2010.532479](https://doi.org/10.3109/1040841X.2010.532479). [PubMed: [21271798](https://pubmed.ncbi.nlm.nih.gov/21271798/)].
22. Cao ZW, Han LY, Zheng CJ, Ji ZL, Chen X, Lin HH, et al. Computer prediction of drug resistance mutations in proteins. *Drug Discov Today.* 2005;**10**(7):521–9. doi: [10.1016/S1359-6446\(05\)03377-5](https://doi.org/10.1016/S1359-6446(05)03377-5). [PubMed: [15809198](https://pubmed.ncbi.nlm.nih.gov/15809198/)].
23. Rumbaugh KP, Griswold JA, Iglewski BH, Hamood AN. Contribution of quorum sensing to the virulence of *Pseudomonas aeruginosa* in burn wound infections. *Infect Immun.* 1999;**67**(11):5854–62. [PubMed: [10531240](https://pubmed.ncbi.nlm.nih.gov/10531240/)]. [PubMed Central: [PMC969666](https://pubmed.ncbi.nlm.nih.gov/PMC969666/)].
24. Golpasha ID, Mousavi SF, Owlia P, Siadat SD, Irani S. Immunization with 3-oxododecanoyl-L-homoserine lactone-r-PcrV conjugate enhances survival of mice against lethal burn infections caused by *Pseudomonas aeruginosa*. *Bosn J Basic Med Sci.* 2015;**15**(2):15–24. doi: [10.17305/bjbm.2015.292](https://doi.org/10.17305/bjbm.2015.292). [PubMed: [26042508](https://pubmed.ncbi.nlm.nih.gov/26042508/)]. [PubMed Central: [PMC4469931](https://pubmed.ncbi.nlm.nih.gov/PMC4469931/)].
25. Coetzee E, Rode H, Kahn D. *Pseudomonas aeruginosa* burn wound infection in a dedicated paediatric burns unit. *S Afr J Surg.* 2013;**51**(2):50–3. doi: [10.7196/sajs.i134](https://doi.org/10.7196/sajs.i134). [PubMed: [23725892](https://pubmed.ncbi.nlm.nih.gov/23725892/)].
26. Izadi Pour Jahromi S, Mardaneh J, Sharifi A, Pezeshkpour V, Behzad-Bebahani A, Seyyedi N, et al. Occurrence of a multidrug resistant *pseudomonas aeruginosa* strains in hospitalized patients in south west of Iran: Characterization of resistance trends and virulence determinants. *Jundishapur J Microbiol.* 2018;**11**(4). doi: [10.5812/jjm.57341](https://doi.org/10.5812/jjm.57341).
27. Japioni A, Farshad S, Alborzi A. *Pseudomonas aeruginosa*: Burn infection, treatment and antibacterial resistance. *Iran Red Crescent Med J.* 2009;**11**(3):244–53.
28. Wilder CN, Diggie SP, Schuster M. Cooperation and cheating in *Pseudomonas aeruginosa*: the roles of the las, rhl and pqs quorum-sensing systems. *ISME J.* 2011;**5**(8):1332–43. doi: [10.1038/ismej.2011.13](https://doi.org/10.1038/ismej.2011.13). [PubMed: [21368905](https://pubmed.ncbi.nlm.nih.gov/21368905/)]. [PubMed Central: [PMC3146268](https://pubmed.ncbi.nlm.nih.gov/PMC3146268/)].
29. Winstanley C, O'Brien S, Brockhurst MA. *Pseudomonas aeruginosa* evolutionary adaptation and diversification in cystic fibrosis chronic lung infections. *Trends Microbiol.* 2016;**24**(5):327–37. doi: [10.1016/j.tim.2016.01.008](https://doi.org/10.1016/j.tim.2016.01.008). [PubMed: [26946977](https://pubmed.ncbi.nlm.nih.gov/26946977/)]. [PubMed Central: [PMC4854172](https://pubmed.ncbi.nlm.nih.gov/PMC4854172/)].
30. D'Argenio DA, Wu M, Hoffman LR, Kulasekara HD, Deziel E, Smith EE, et al. Growth phenotypes of *Pseudomonas aeruginosa* lasR mutants adapted to the airways of cystic fibrosis patients. *Mol Microbiol.* 2007;**64**(2):512–33. doi: [10.1111/j.1365-2958.2007.05678.x](https://doi.org/10.1111/j.1365-2958.2007.05678.x). [PubMed: [17493132](https://pubmed.ncbi.nlm.nih.gov/17493132/)]. [PubMed Central: [PMC2742308](https://pubmed.ncbi.nlm.nih.gov/PMC2742308/)].
31. Feliziani S, Lujan AM, Moyano AJ, Sola C, Bocco JL, Montanaro P, et al. Mucoidy, quorum sensing, mismatch repair and antibiotic resistance in *Pseudomonas aeruginosa* from cystic fibrosis chronic airways infections. *PLoS One.* 2010;**5**(9). doi: [10.1371/journal.pone.0012669](https://doi.org/10.1371/journal.pone.0012669). [PubMed: [20844762](https://pubmed.ncbi.nlm.nih.gov/20844762/)]. [PubMed Central: [PMC2937033](https://pubmed.ncbi.nlm.nih.gov/PMC2937033/)].
32. López-Causapé C, Sommer LM, Cabot G, Rubio R, Ocampo-Sosa AA, Johansen HK, et al. Evolution of the *Pseudomonas aeruginosa* mutational resistome in an international Cystic Fibrosis clone. *Sci Rep.* 2017;**7**(1):5555. doi: [10.1038/s41598-017-05621-5](https://doi.org/10.1038/s41598-017-05621-5). [PubMed: [28717172](https://pubmed.ncbi.nlm.nih.gov/28717172/)]. [PubMed Central: [PMC5514035](https://pubmed.ncbi.nlm.nih.gov/PMC5514035/)].
33. Lima J, Alves LR, Jacome P, Bezerra Neto JP, Maciel MAV, Morais MMC. Biofilm production by clinical isolates of *Pseudomonas aeruginosa* and structural changes in LasR protein of isolates non biofilm-producing. *Braz J Infect Dis.* 2018;**22**(2):129–36. doi: [10.1016/j.bjid.2018.03.003](https://doi.org/10.1016/j.bjid.2018.03.003). [PubMed: [29601791](https://pubmed.ncbi.nlm.nih.gov/29601791/)].
34. Cao H, Lai Y, Bougouffa S, Xu Z, Yan A. Comparative genome and transcriptome analysis reveals distinctive surface characteristics and unique physiological potentials of *Pseudomonas aeruginosa* ATCC 27853. *BMC Genomics.* 2017;**18**(1):459. doi: [10.1186/s12864-017-3842-z](https://doi.org/10.1186/s12864-017-3842-z). [PubMed: [28606056](https://pubmed.ncbi.nlm.nih.gov/28606056/)]. [PubMed Central: [PMC5467263](https://pubmed.ncbi.nlm.nih.gov/PMC5467263/)].
35. Kitao T, Lepine F, Babloui S, Walte F, Steinbacher S, Maskos K, et al. Molecular insights into function and competitive inhibition of *Pseudomonas aeruginosa* multiple virulence factor regulator. *MBio.* 2018;**9**(1). doi: [10.1128/mBio.02158-17](https://doi.org/10.1128/mBio.02158-17). [PubMed: [29339431](https://pubmed.ncbi.nlm.nih.gov/29339431/)]. [PubMed Central: [PMC5770554](https://pubmed.ncbi.nlm.nih.gov/PMC5770554/)].
36. Zhang Z, Miteva MA, Wang L, Alexov E. Analyzing effects of naturally occurring missense mutations. *Comput Math Methods Med.* 2012;**2012**:805827. doi: [10.1155/2012/805827](https://doi.org/10.1155/2012/805827). [PubMed: [22577471](https://pubmed.ncbi.nlm.nih.gov/22577471/)]. [PubMed Central: [PMC3346971](https://pubmed.ncbi.nlm.nih.gov/PMC3346971/)].
37. Zhou H, Gao M, Skolnick J. ENTPRISE-X: Predicting disease-associated frameshift and nonsense mutations. *PLoS One.* 2018;**13**(5). e0196849. doi: [10.1371/journal.pone.0196849](https://doi.org/10.1371/journal.pone.0196849). [PubMed: [29723276](https://pubmed.ncbi.nlm.nih.gov/29723276/)]. [PubMed Central: [PMC5933770](https://pubmed.ncbi.nlm.nih.gov/PMC5933770/)].
38. Yamaguchi-Kabata Y, Shimada MK, Hayakawa Y, Minoshima S, Chakraborty R, Gojobori T, et al. Distribution and effects of nonsense polymorphisms in human genes. *PLoS One.* 2008;**3**(10). e3393. doi: [10.1371/journal.pone.0003393](https://doi.org/10.1371/journal.pone.0003393). [PubMed: [18852891](https://pubmed.ncbi.nlm.nih.gov/18852891/)]. [PubMed Central: [PMC2561068](https://pubmed.ncbi.nlm.nih.gov/PMC2561068/)].